-
05:41:58 PM

GH Stock News

03/21/23 8:05 AM
Nasdaq : GH
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
Guardant Health, Inc., a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center– Arthur G. James Cancer Hospital and Richard J. Solove Research Institute to evaluate patient compliance with a blood-based test for colorectal cancer screening.
RHEA-AI
neutral
03/10/23 8:05 AM
Nasdaq : GH
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Guardant Health, Inc., a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration the final module of its premarket approval application for Shield™, Guardant Health’ s blood test to screen for colorectal cancer. We are looking forward to partnering with the agency on bringing this life-saving test to the...
RHEA-AI
neutral
02/23/23 4:05 PM
Nasdaq : GH
earnings
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth...
RHEA-AI
neutral
02/15/23 8:05 AM
Nasdaq : GH
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Guardant Health, Inc., a leading precision oncology company, announced the initiation of a new study to examine patient preference for Shield, Guardant Health’ s blood test to screen for colorectal cancer, and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity– University...
RHEA-AI
neutral
02/08/23 8:05 AM
Nasdaq : GH
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Guardant Health, Inc., a leading precision oncology company, announced today that UnitedHealthcare now covers the Guardant360 ® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA- approved companion diagnostic indications. “We are pleased that UnitedHealthcare has taken this important step to make comprehensive genomic...
RHEA-AI
very positive
02/02/23 8:05 AM
Nasdaq : GH
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Guardant Health Inc., a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today a strategic collaboration on the development, regulatory approval and commercialization of the Guardant360...
RHEA-AI
very positive
02/02/23 6:00 AM
Nasdaq : GH
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
Guardant Health, Inc., a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed:. Guardant Health is a leading precision...
RHEA-AI
neutral
02/01/23 4:05 PM
Nasdaq : GH
conferencesearnings
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Guardant Health, Inc., a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and...
RHEA-AI
neutral